Closing
Do DPP-4 inhibitors improve kidney outcomes versus placebo?
Mostly studied in type 2 & unspecified diabetes. Also asked against other treatments.
Not modeled yetTrial evidence exists, but no mechanistic model yetWithout a model there is no decisive experiment to propose. Help build it. →
Where the evidence stands
Doubtful. So far, no trial evidence yet.
NoUnsureYes
- Belief
- 0.25 (range 0.10–0.70)
- Trials for
- 0
- Trials against
- 0
- Inconclusive
- 1
Already under way
- Open-label, Double-arm, Controlled, Randomized, Multicentre Clinical Trial to Evaluate the Impact of Pharmacogenetic-guided Treatment in Patients With…NCT06851962 · active not recruiting · started 2025
- A Multicenter, Prospective, Non-interventional Observation Study to Evaluate the Safety and Effectiveness of OAD Triple Therapy in Korean Type 2 Diabetic…NCT06838286 · recruiting · started 2024
- Effect of Empagliflozin Versus Linagliptin on Glycemic Outcomes, Renal Outcomes and Body Composition in Renal Transplant Recipients With Diabetes Mellitus:…NCT06095492 · recruiting · started 2023
- Comparative Analysis of Cost-effectiveness Between Sulfonylureas and DPP4 Inhibitors in Combination With Metformin in Treatment of Type 2 Diabetic Patients : A…NCT06570980 · recruiting · started 2023
- Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes StudyNCT05220917 · active not recruiting · started 2021
The evidence so far
- Registered trials
- 46
- With posted results
- 13
- Published papers
- 0
Of 2 decided analyses: 0 favor dpp-4 inhibitors, 2 find no difference, 0 favor the comparator.
Trials
- Post-authorisation Safety Study in Patients With Type 2 Diabetes Mellitus to Assess the Risk of Acute Liver Injury, Acute Kidney Injury and Chronic Kidney Disease, Severe Complications of Urinary Tract Infection, Genital Infections, and Diabetic Ketoacidosis Among Patients Treated With Empagliflozin Compared to Patients Treated With DPP-4 InhibitorsNCT02864914 · 6 posted results
- A Randomized, Double-Blind, Placebo-Controlled, Double-Dummy, Parallel Group, Multicenter, Dose-Ranging Study in Subjects With Type 2 Diabetes Mellitus to Evaluate the Efficacy, Safety, and Tolerability of Orally Administered SGLT2 Inhibitor JNJ-28431754 With Sitagliptin as a Reference ArmNCT00642278 · 6 posted results
- Does Glycated Hemoglobin Variability in Type 2 Diabetes Differ Depending on the Diabetes Treatment Threshold Used in the Qatari Population: Implication on Diabetes Complication Risk?NCT02879409
- Use of Combination Empagliflozin/Linagliptin or Dapagliflozin/Saxagliptin vs Empagliflozin or Dapagliflozin Alone, Subclinical Inflammation of the Genito-urinary Tract and Risk of Infections.NCT04735042
- Effect of Empagliflozin Versus Linagliptin on Glycemic Outcomes, Renal Outcomes and Body Composition in Renal Transplant Recipients With Diabetes Mellitus: Randomized Controlled TrialNCT06098625
- Effect of Empagliflozin Versus Linagliptin on Glycemic Outcomes, Renal Outcomes and Body Composition in Renal Transplant Recipients With Diabetes Mellitus: Randomized Controlled Trial (EmLina Renal Trial)NCT06095492
- Comparison of Empaglifozin and Vildagliptin in Efficacy and Safety in Type 2 Diabetes MellitusNCT05359432
- A Retrospective Database Assessment of Clinical Effectiveness in Type 2 Diabetes Patients Treated With Liraglutide From Primary Care Centers in SwedenNCT02077946